id	author	title	date	pages	extension	mime	words	sentences	flesch	summary	cache	txt
work_4bagrmqurjcpbfmvzqdlvhecne	Judith A. Gilbert	Molecular Markers for Novel Therapeutic Strategies in Pancreatic Endocrine Tumors	2013.0	11	.pdf	application/pdf	9581	2330	70	Pancreatic endocrine tumors (PETs), including islet cell carci-nomas, account for 1% to 3% of all pancreatic cancers.1 An research into targeting Hsp90, IGF1R, and EGFR for development of new therapeutic strategies for some carcinoid tumors. receptors and downstream regulators examined earlier in carcinoid tumors.7 The genetic abnormalities analyzed were biomarkers of response to targeted therapeutics developed for other latter a biomarker predictive of sensitivity to gefitinib in nonsmall-cell lung cancer10,11 and to anti-EGFR monoclonal antibodies cetuximab and panitumumab in colorectal cancer.12Y14 assays performed with QGP-1 cells determined that growth inhibition was produced by increasing concentrations of the following therapeutic agents: axitinib and sunitinib (TKIs targeting B, Effect of increasing concentrations of anticancer drug 17-AAG (targeting Hsp90) on QGP-1 cell growth and levels of indicated (targeting VEGFR1-3, PDGFRA-B, and KIT) on QGP-1 cell growth and levels of indicated biomarkers, with experiments performed as	./cache/work_4bagrmqurjcpbfmvzqdlvhecne.pdf	./txt/work_4bagrmqurjcpbfmvzqdlvhecne.txt